Erectile dysfunction

R Shamloul, H Ghanem - The Lancet, 2013 - thelancet.com
Erectile dysfunction is a common clinical entity that affects mainly men older than 40 years.
In addition to the classical causes of erectile dysfunction, such as diabetes mellitus and …

cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action

SH Francis, JL Busch, JD Corbin, D Sibley - Pharmacological reviews, 2010 - Elsevier
To date, studies suggest that biological signaling by nitric oxide (NO) is primarily mediated
by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by …

When “chems” meet sex: a rising phenomenon called “chemsex”

R Giorgetti, A Tagliabracci, F Schifano… - Current …, 2017 - ingentaconnect.com
Background: The term “chemsex” was coined to indicate the voluntary intake of psychoactive
and non psychoactive drugs in the context of recreational settings to facilitate and/or to …

Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction

KE Andersson, MC Michel - Pharmacological reviews, 2011 - Elsevier
Erection is basically a spinal reflex that can be initiated by recruitment of penile afferents,
both autonomic and somatic, and supraspinal influences from visual, olfactory, and …

Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease

N Tzoumas, TE Farrah, N Dhaun… - British Journal of …, 2020 - Wiley Online Library
PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of
drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the …

Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review

AA Ganapathy, VMH Priya, A Kumaran - Journal of Ethnopharmacology, 2021 - Elsevier
Ethnopharmacological relevance The prevalence and distress caused by erectile
dysfunction (ED) to both male and female partners are increasing at a steady rate. ED has …

Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient

G Corona, N Mondaini, A Ungar… - The Journal of …, 2011 - academic.oup.com
Introduction Erectile dysfunction (ED) is a very common multidimensional disorder affecting
men worldwide. Physical illness, reaction to life stresses, or an unhappy couple relationship …

[HTML][HTML] Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents

P Pantziarka, V Sukhatme, S Crispino… - …, 2018 - ncbi.nlm.nih.gov
Selective phosphodiesterase 5 inhibitors, including sildenafil, tadalafil and vardenafil, are
widely-used in the treatment of erectile dysfunction and pulmonary arterial hypertension …

The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

E Ventimiglia, P Capogrosso, F Montorsi… - Expert opinion on drug …, 2016 - Taylor & Francis
Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the
treatment of erectile dysfunction (ED), being recommended as a first line treatment by both …

The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats

HM Mansour, AAA Salama… - Canadian Journal of …, 2018 - cdnsciencepub.com
Liver fibrosis is a health concern that leads to organ failure mediated via production of
inflammatory cytokines and fibrotic biomarkers. This study aimed to explore the protective …